What’s New and Updates/Changes

Updates, Clarifications, and Corrections
Friday, March 21, 2014

Notable changes are highlighted in yellow for approximately 1 month.

Retreatment Box (Summary). Recommendations for Patients in Whom Previous PEG/RBV Treatment Has Failed

For patients with genotype 1 HCV and prior PEG/RBV failure the treatment duration of PEG/RBV in the alternate regimen SMV/PEG/RBV has been corrected to 48 weeks; for patients with genotype 4 HCV and prior PEG/RBV failure, SOF +RBV x 24 weeks was corrected to be listed as an alternative regimen and SMV/ PEG/RBV was removed as an alternative; for patients with genotype 5 or 6 HCV the incorrect listing of SOF/RBV as an alternative regimen was removed.

For patients with prior PEG/RBV/HCV protease inhibitor failure, this portion of the box was reformatted for clarity and alternative regimens by IFN eligibility have been listed.

Retreatment of Persons in Whom Prior Therapy Has Failed

1, Genotype 1. The recommended regimen for prior failures of PEG/RBV/HCV protease inhibitor regimens was added for clarity; the alternative regimen; the alternative regimen (and supporting text) for IFN ineligible patients was added.

Unique Patient Populations: HIV/HCV Coinfection Summary

Tipranavir (as described in the text) was added to the table of not allowable with SOF use.

New Panel Members
Tuesday, March 18, 2014

We are pleased to announce a new member to the HCV Guidance Panel: Hugo E. Vargas, MD, of the College of Medicine, Mayo Clinic.

Wednesday, March 12, 2014

NOTICE: Guidance for hepatitis C treatment is changing constantly with the advent of new therapies and other developments. A static version of this guidance, such as printout of this website material, booklet, slides, and other materials, may be outdated by the time you read this. We urge you to review this guidance on this website (www.hcvguidelines.org) for the latest recommendations.

Access the Full Report
Thursday, February 13, 2014

The printable version of the Full Report is now available online!

Official Press Release
Wednesday, January 29, 2014